Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label vs Double-blind Placebo and Peppermint Oil in IBS
NCT02802241Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Jun 2016
- Primary completion
- Jan 2019
- Countries
- 1
01
Overview
Randomised, double-blind trial in irritable bowel syndrome (IBS) (4 arms), sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Irritable Bowel Syndrome Symptom Severity Score at 6 weeks. Started Jun 2016; status: completed.
02
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT02802241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02802241.